SARS-COV-2 immune response dynamics to vaccines in African populations
Research type
Research Study
Full title
SARS-COV-2 immune response dynamics to vaccines in African populations
IRAS ID
309527
Contact name
Ravindra Gupta
Contact email
Sponsor organisation
University of Cambridge
Duration of Study in the UK
2 years, 0 months, 3 days
Research summary
Vaccines designed to elicit protective immune responses are the cornerstone of the global strategy against the COVID-19 pandemic. Following vaccination, neutralising antibodies become detectable and are expected to be protective against symptomatic SARS-CoV-2 infection and transmission of the virus. However, the rapid global spread of variants of concern, especially the Delta variant (B.617.2), threatens global vaccine security. Emerging data suggest that the Delta variant demonstrates reduced sensitivity to vaccine-induced neutralising antibodies and much higher particle infectivity. There are very limited data on SARS-CoV-2 vaccine immunogenicity and durability of vaccine- induced immune protection in west African populations across the diversity of licensed vaccines, including in people living with HIV (PLWH) in this HIV high-prevalence setting. We aim to characterise responses to COVID vaccines in the general population and HIV population.
REC name
London - Surrey Research Ethics Committee
REC reference
23/PR/0586
Date of REC Opinion
15 Jun 2023
REC opinion
Favourable Opinion